Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "API"

2345 News Found

Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma
Drug Approval | September 29, 2024

Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma

Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations


Lupin signs distribution agreement with Celnova for orphan drug NaMuscla
Supply Chain | September 28, 2024

Lupin signs distribution agreement with Celnova for orphan drug NaMuscla

Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia


FDA approves Bristol Myers Squibb’s Cobenfy
Drug Approval | September 28, 2024

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults


India releases revised operational guidelines of non-alcoholic fatty liver disease
Policy | September 28, 2024

India releases revised operational guidelines of non-alcoholic fatty liver disease

India has taken the lead in recognising NAFLD as a major non-communicable disease


Krsnaa Diagnostics acquires stake in Apulki Healthcare
News | September 27, 2024

Krsnaa Diagnostics acquires stake in Apulki Healthcare

Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita


Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis
News | September 27, 2024

Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis

Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism


Briefs: Krsnaa Diagnostics and Anuh Pharma
News | September 27, 2024

Briefs: Krsnaa Diagnostics and Anuh Pharma

Krsnaa Diagnostics receives LoI from RINPAS for radiology services


BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
Diagnostic Center | September 27, 2024

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts


Dr. Morepen’s diabetes awareness campaign kicks on KBC
Healthcare | September 25, 2024

Dr. Morepen’s diabetes awareness campaign kicks on KBC

This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets